RMC No. 62-2025: Publishing the full text of the May 15, 2025 Letter from the Food and Drug Administration of the Department of Health endorsing updates to the List of VAT-Exempt Products Under RA No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act)

Summary

RMC No. 62-2025 publishes the full text of the May 15, 2025 letter from the FDA endorsing updates to the List of VAT-Exempt Products under RA No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act).

Key points

1. Changes to the list. The letter, from FDA Director General Paolo S. Teston, adds certain medicines for cancer, diabetes, high cholesterol, hypertension and mental diseases tuberculosis. It also deletes certain medicine for cancer.
2. Effectivity of exemption. As clarified in Q&A No. 1 of RMC No. 99-2021, the VAT exemption of covered medicines and medical devices under the CREATE Act takes effect on the date the FDA publishes the list updates.

Deadlines and effectivity

• VAT exemption effective on the date of FDA publication of the list updates

Summary by Tax Resources PH. It is not a substitute for the full text of the issuance or professional advice.